MedTrace Logo

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

NCT00698828 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.

Conditions

  • Cachexia

Interventions

DRUG

Placebo comparator

Twice daily subcutaneous injections of placebo for 12 weeks.

DRUG

SUN11031 20 μg/kg

Twice daily subcutaneous injections of SUN11031 20 μg/kg for 12 weeks.

DRUG

SUN11031 40 μg/kg

Twice daily subcutaneous injections of SUN11031 40 μg/kg for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-15
Primary Completion
2009-10-08
Completion
2009-10-08
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Chile
  • Guatemala
  • Honduras
  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698828 on ClinicalTrials.gov